预测经皮冠状动脉介入治疗后出血的 PRECISE-HBR 评分的推导和验证。

IF 5.2 3区 工程技术 Q2 ENERGY & FUELS
Felice Gragnano, David van Klaveren, Dik Heg, Lorenz Räber, Mitchell W Krucoff, Sergio Raposeiras-Roubän, Jurriën M Ten Berg, Sergio Leonardi, Takeshi Kimura, Noé Corpataux, Alessandro Spirito, James B Hermiller, Emad Abu-Assi, Dean Chan Pin Yin, Jaouad Azzahhafi, Claudio Montalto, Marco Galazzi, Sarah Bär, Raminta Kavaliauskaite, Fabrizio D'Ascenzo, Gaetano M De Ferrari, Hirotoshi Watanabe, Philippe Gabriel Steg, Deepak L Bhatt, Paolo Calabrò, Roxana Mehran, Philip Urban, Stuart Pocock, Stephan Windecker, Marco Valgimigli
{"title":"预测经皮冠状动脉介入治疗后出血的 PRECISE-HBR 评分的推导和验证。","authors":"Felice Gragnano, David van Klaveren, Dik Heg, Lorenz Räber, Mitchell W Krucoff, Sergio Raposeiras-Roubän, Jurriën M Ten Berg, Sergio Leonardi, Takeshi Kimura, Noé Corpataux, Alessandro Spirito, James B Hermiller, Emad Abu-Assi, Dean Chan Pin Yin, Jaouad Azzahhafi, Claudio Montalto, Marco Galazzi, Sarah Bär, Raminta Kavaliauskaite, Fabrizio D'Ascenzo, Gaetano M De Ferrari, Hirotoshi Watanabe, Philippe Gabriel Steg, Deepak L Bhatt, Paolo Calabrò, Roxana Mehran, Philip Urban, Stuart Pocock, Stephan Windecker, Marco Valgimigli","doi":"10.1161/CIRCULATIONAHA.124.072009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.</p><p><strong>Methods: </strong>The derivation cohort comprised 29,188 patients undergoing PCI, of whom 1136 (3.9%) had a Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from four contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis (p<0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial and 5970 patients from the STOPDAPT-2 total cohort.</p><p><strong>Results: </strong>The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white-blood-cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71-0.74) at apparent validation, 0.72 (95% CI, 0.70-0.73) at cross-validation, 0.74 (95% CI, 0.68-0.80) in the MASTER DAPT, and 0.73 (95% CI, 0.66-0.79) in the STOPDAPT-2, with superior discrimination than the PRECISE-DAPT (cross-validation: Δ AUC, 0.01; p=0.02; MASTER DAPT: Δ AUC, 0.05; p=0.004; STOPDAPT-2: Δ AUC, 0.02; p=0.20) and other risk scores. In the derivation cohort, a cut-off of 23 points identified 11,414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white-blood-cell count, showed similar predictive ability.</p><p><strong>Conclusions: </strong>The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.</p>","PeriodicalId":35,"journal":{"name":"Energy & Fuels","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention.\",\"authors\":\"Felice Gragnano, David van Klaveren, Dik Heg, Lorenz Räber, Mitchell W Krucoff, Sergio Raposeiras-Roubän, Jurriën M Ten Berg, Sergio Leonardi, Takeshi Kimura, Noé Corpataux, Alessandro Spirito, James B Hermiller, Emad Abu-Assi, Dean Chan Pin Yin, Jaouad Azzahhafi, Claudio Montalto, Marco Galazzi, Sarah Bär, Raminta Kavaliauskaite, Fabrizio D'Ascenzo, Gaetano M De Ferrari, Hirotoshi Watanabe, Philippe Gabriel Steg, Deepak L Bhatt, Paolo Calabrò, Roxana Mehran, Philip Urban, Stuart Pocock, Stephan Windecker, Marco Valgimigli\",\"doi\":\"10.1161/CIRCULATIONAHA.124.072009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.</p><p><strong>Methods: </strong>The derivation cohort comprised 29,188 patients undergoing PCI, of whom 1136 (3.9%) had a Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from four contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis (p<0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial and 5970 patients from the STOPDAPT-2 total cohort.</p><p><strong>Results: </strong>The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white-blood-cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71-0.74) at apparent validation, 0.72 (95% CI, 0.70-0.73) at cross-validation, 0.74 (95% CI, 0.68-0.80) in the MASTER DAPT, and 0.73 (95% CI, 0.66-0.79) in the STOPDAPT-2, with superior discrimination than the PRECISE-DAPT (cross-validation: Δ AUC, 0.01; p=0.02; MASTER DAPT: Δ AUC, 0.05; p=0.004; STOPDAPT-2: Δ AUC, 0.02; p=0.20) and other risk scores. In the derivation cohort, a cut-off of 23 points identified 11,414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white-blood-cell count, showed similar predictive ability.</p><p><strong>Conclusions: </strong>The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.</p>\",\"PeriodicalId\":35,\"journal\":{\"name\":\"Energy & Fuels\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2024-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Energy & Fuels\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1161/CIRCULATIONAHA.124.072009\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENERGY & FUELS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Energy & Fuels","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCULATIONAHA.124.072009","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENERGY & FUELS","Score":null,"Total":0}
引用次数: 0

摘要

背景:经皮冠状动脉介入治疗(PCI)后准确的出血风险分层对治疗个体化非常重要。然而,对高出血风险患者进行更精确、更标准化的识别仍是一个亟待解决的问题。我们利用高出血风险学术研究联盟(ARC-HBR)标准增强了 PRECISE-DAPT 评分,从而得出并验证了一种新型出血风险评分:衍生队列包括 29,188 名接受 PCI 治疗的患者,其中 1136 人(3.9%)在 1 年后出现出血学术研究联盟 (BARC) 3 级或 5 级出血,这些患者来自四个当代真实世界登记处和 XIENCE V USA 试验。PRECISE-DAPT评分在衍生队列中使用Fine-Gray模型重新拟合,并根据ARC-HBR标准进行扩展。主要结果是 1 年内 BARC 3 或 5 出血。多变量分析筛选出了 BARC 3 或 5 期出血的独立预测因素(pResults:PRECISE-HBR评分(年龄、估计肾小球滤过率、血红蛋白、白细胞计数、既往出血、口服抗凝药和ARC-HBR标准)显示,在表观验证时,1年内BARC 3或5出血的曲线下面积(AUC)为0.73(95% CI,0.71-0.74),交叉验证时为0.72(95% CI,0.70-0.73),交叉验证时MASTER DAPT为0.74(95% CI,0.68-0.80),STOPDAPT-2为0.73(95% CI,0.66-0.79),分辨力优于PRECISE-DAPT(交叉验证:Δ AUC,0.01;p=0.02;MASTER DAPT:Δ AUC,0.05;p=0.004;STOPDAPT-2:Δ AUC,0.02;p=0.20)和其他风险评分相比具有更高的区分度。在推导队列中,以 23 分为临界值确定了 11,414 名患者(39.1%)1 年 BARC 3 或 5 级出血风险≥4%。该评分的另一个版本包括入院时的急性心肌梗死而不是白细胞计数,也显示出类似的预测能力:PRECISE-HBR评分是预测PCI术后出血的一个现代、简单的7项风险评分,与现有的多个评分相比,其辨别能力有一定程度的提高。需要进一步评估其对临床实践的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention.

Background: Accurate bleeding risk stratification after percutaneous coronary intervention (PCI) is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of high bleeding risk patients. We derived and validated a novel bleeding risk score by augmenting the PRECISE-DAPT score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria.

Methods: The derivation cohort comprised 29,188 patients undergoing PCI, of whom 1136 (3.9%) had a Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from four contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis (p<0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial and 5970 patients from the STOPDAPT-2 total cohort.

Results: The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white-blood-cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71-0.74) at apparent validation, 0.72 (95% CI, 0.70-0.73) at cross-validation, 0.74 (95% CI, 0.68-0.80) in the MASTER DAPT, and 0.73 (95% CI, 0.66-0.79) in the STOPDAPT-2, with superior discrimination than the PRECISE-DAPT (cross-validation: Δ AUC, 0.01; p=0.02; MASTER DAPT: Δ AUC, 0.05; p=0.004; STOPDAPT-2: Δ AUC, 0.02; p=0.20) and other risk scores. In the derivation cohort, a cut-off of 23 points identified 11,414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white-blood-cell count, showed similar predictive ability.

Conclusions: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after PCI, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Energy & Fuels
Energy & Fuels 工程技术-工程:化工
CiteScore
9.20
自引率
13.20%
发文量
1101
审稿时长
2.1 months
期刊介绍: Energy & Fuels publishes reports of research in the technical area defined by the intersection of the disciplines of chemistry and chemical engineering and the application domain of non-nuclear energy and fuels. This includes research directed at the formation of, exploration for, and production of fossil fuels and biomass; the properties and structure or molecular composition of both raw fuels and refined products; the chemistry involved in the processing and utilization of fuels; fuel cells and their applications; and the analytical and instrumental techniques used in investigations of the foregoing areas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信